Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation - PubMed (original) (raw)

. 2009 Jun;145(6):816-24.

doi: 10.1111/j.1365-2141.2009.07674.x. Epub 2009 Mar 26.

Brent Logan, Dan Wang, Mary Horowitz, Joseph P Uberti, Olle Ringden, Robert Peter Gale, Hanna Khoury, Mukta Arora, Stephen Spellman, Corey Cutler, Joseph Antin, Martin Bornhaüser, Gregory Hale, Leo Verdonck, Mitchell Cairo, Vikas Gupta, Steven Pavletic; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

Affiliations

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

Voravit Ratanatharathorn et al. Br J Haematol. 2009 Jun.

Abstract

Prior therapy with rituximab might attenuate disparate histocompatibility antigen presentation by B cells, thus decreased the risk of acute graft-versus-host disease (GVHD) and improved survival. We tested this hypothesis by comparing the outcomes of 435 B-cell lymphoma patients who received allogeneic transplantation from 1999 to 2004 in the Center for International Blood and Marrow Transplant Research database: 179 subjects who received rituximab within 6 months prior to transplantation (RTX cohort) and 256 subjects who did not receive RTX within 6 months prior to transplantation (No-RTX cohort). The RTX cohort had a significantly lower incidence of treatment-related mortality (TRM) [relative risk (RR) = 0.68; 95% confidence interval (CI), 0.47-1.0; P = 0.05], lower acute grade II-IV (RR = 0.72; 95% CI, 0.53-0.97; P = 0.03) and III-IV GVHD (RR = 0.55; 95% CI, 0.34-0.91; P = 0.02). There was no difference in the risk of chronic GVHD, disease progression or relapse. Progression-free survival (PFS) (RR = 0.68; 95% CI 0.50-0.92; P = 0.01) and overall survival (OS) (RR = 0.63; 95% CI, 0.46-0.86; P = 0.004) were significantly better in the RTX cohort. Prior RTX therapy correlated with less acute GVHD, similar chronic GVHD, less TRM, better PFS and OS.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declared no financial interests.

Figures

Figure 1

Figure 1. Panel A Cumulative incidence of grade 2-4 acute GVHD; Panel B Cumulative incidence of grade 3-4 acute GVHD; Panel C Progression-free survival; Panel D Overall survival

Similar articles

Cited by

References

    1. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology. 1998;9:995–1001. - PubMed
    1. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603–2606. - PubMed
    1. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310. - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine. 2002;346:235–242. - PubMed
    1. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society Series B (Methodological) 1972;34:187–220.

Publication types

MeSH terms

Substances

LinkOut - more resources